Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort

Fixed-duration (not MRD-guided) ibrutinib-venetoclax cohort. In the all-treated population, CR 55% (95% CI 48-63); best uMRD 77% (PB) and 60% (BM); 24-month PFS 95% and OS 98%. Level 2.

BloodPubMed 35196370